Table 6. Multivariate analysis of prognostic factors associated with survival in sensitive and refractory patients.
| Variables | Sensitive LS-SCLC | Refractory LS-SCLC | ||||
|---|---|---|---|---|---|---|
| MST | HR (95% CI) | p | MST | HR (95% CI) | p | |
| Numbers of cycle | ||||||
| N ≥ 4 | 23.8 | 0.598 0.345–1.034 | 0.066 | 18.3 | 0.515 0.306–0.865 | 0.012 |
| N < 4 | 17.5 | Ref. | 13.1 | Ref. | ||
| Response | ||||||
| CR + PR | 24.5 | 0.571 0.309–1.068 | 0.083 | 18.4 | 0.683 0.512–0.906 | 0.011 |
| PD + SD | 17.1 | Ref. | 14.2 | Ref. | ||
| Treatment Modality | ||||||
| Chemoradiotherapy | 24.7 | 0.528 0.315–0.878 | 0.016 | 18.0 | 0.738 0.552–0.943 | 0.023 |
| Chemotherapy | 16.6 | Ref. | 14.6 | Ref. | ||
| LDH | ||||||
| Elevated (> 240 U/l) | 18.1 | 2.610 1.862–3.679 | < 0.001 | 13.7 | 2.313 1.556–3.417 | < 0.001 |
| Normal (≤ 240 U/l) | 26.4 | Ref. | 19.2 | Ref. | ||
| NLR | ||||||
| Elevated (≥ 4) | 18.4 | 1.538 1.072–2.214 | 0.024 | 14.1 | 1.677 1.110–2.524 | 0.013 |
| Normal (< 4) | 25.6 | Ref. | 18.6 | Ref. | ||
Abbreviations: LS-SCLC: limited-stage small cell lung cancer; MST: median survival time; HR: hazard ratio; CI: confidence interval; CR: complete response; PR: partial response; SD: disease stable; PD: disease progression; LDH: lactate dehydrogenase; NLR: neutrophil-to-lymphocyte ratio.